Results 181 to 190 of about 54,594 (319)

Precision medicine in cutaneous melanoma—A comprehensive review

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Precision medicine tailors treatment to each patient, beginning with detailed diagnostics. In melanoma, it has advanced considerably: Some methods are in practice and guidelines, while others are commercially available but not routine. This review highlights current and emerging approaches, including molecular profiling, imaging, biomarkers and AI ...
Markus Reitmajer, Lukas Flatz
wiley   +1 more source

Acute lymphoblastic B‐cell leukemia or CAR‐T cell related skin changes – a relevant diagnostic challenge

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Farzan Solimani   +9 more
wiley   +1 more source

Targeting Tumor Dormancy and Recurrence: Molecular Mechanisms and Peptide Therapeutic Delivery

open access: yesMedComm – Oncology, Volume 5, Issue 1, March 2026.
This review summarizes the molecular mechanisms that regulate tumor dormancy and its role in cancer recurrence, with emphasis on immune evasion, extracellular matrix remodeling, metabolic regulation and angiogenic switching. It further discusses emerging peptide–based therapeutic strategies aimed at detecting, modulating, and eliminating dormant tumor ...
Abdur Raheem Aleem   +9 more
wiley   +1 more source

Harnessing the innate immune system: a novel bispecific antibody targeting CD47 and CD24 for selective tumor clearance. [PDF]

open access: yesJ Immunother Cancer
Nan L   +13 more
europepmc   +1 more source

Incidence and Characteristics of Infectious Complications in Multiple Myeloma Patients Treated With Bispecific Antibodies [PDF]

open access: gold
Taekeun Park   +11 more
openalex   +1 more source

Bispecific antibody toxicities

open access: yesCanadian Medical Association Journal
Britto, Joanne   +3 more
openaire   +2 more sources

Bispecific Antibodies Versus Chimeric Antigen Receptor T‐Cell Therapy in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Comparative Narrative Review of Efficacy, Safety, and Accessibility

open access: yesCancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Introduction Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin lymphoma, and despite advances in frontline therapies such as rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone, approximately 30%–40% of patients develop relapsed or refractory (
Dana Sofian Abou   +6 more
wiley   +1 more source

Non‐Operable Squamous Cell Carcinoma of the Infraorbital Region Treated With Electrochemotherapy: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT Cutaneous squamous cell carcinoma (cSCC) is a malignant epithelial tumor of the skin, classified as a nonmelanoma skin cancer. It may develop from precancerous conditions such as chronic inflammatory dermatoses, actinic keratosis, or actinic cheilitis, but can also arise de novo.
Gianluca Nicolai   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy